KR950704284A - 칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists) - Google Patents

칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists)

Info

Publication number
KR950704284A
KR950704284A KR1019950702552A KR19950702552A KR950704284A KR 950704284 A KR950704284 A KR 950704284A KR 1019950702552 A KR1019950702552 A KR 1019950702552A KR 19950702552 A KR19950702552 A KR 19950702552A KR 950704284 A KR950704284 A KR 950704284A
Authority
KR
South Korea
Prior art keywords
compound
formula
piperidine
hydroxy
pharmaceutically acceptable
Prior art date
Application number
KR1019950702552A
Other languages
English (en)
Inventor
로날드 조세프 킹
토마스 헨리 브라운
데이비드 그윈 쿠퍼
Original Assignee
데이비드 로버츠
스미스클라인 비참 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929226718A external-priority patent/GB9226718D0/en
Priority claimed from GB939321808A external-priority patent/GB9321808D0/en
Application filed by 데이비드 로버츠, 스미스클라인 비참 피엘씨 filed Critical 데이비드 로버츠
Publication of KR950704284A publication Critical patent/KR950704284A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

본 발명은 칼슘 길항제, 예컨대 뇌 세포에서 칼슘의 축적과 관련된 상태의 치료에 유용한 하기 일반식(I)의 화합무 또는 그의 염에 관한 것이다.
상기 식중에서 R1은 C1―6알킬, 할로겐 또는 페닐을 나타내고, R2는 수소 원자, C1―6알킬, 할로겐 또는 페닐을 나타내고 R3는 히드록실 또는 생체내에서 히드록실기로 전환될 수 있는 기이고, R4는 C1―6알킬을 나타내고, p는 0,1 또는 2이고, X는 ―CH2―, ―C〓O, O 또는 S이고, n은 4내지 10의 정수이고, m은 3내지 8의 정수이다.

Description

칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 하기 일반식(I)의 화합물 또는 그의 염.
    (I)
    상기 식중에서 R1은 C1―6알킬, 할로겐 또는 페닐을 나타내고, R2는 수소 원자, C1―6알킬, 할로겐 또는 페닐을 나타내고 R3는 히드록실 또는 생체내에서 히드록실기로 전환될 수 있는 기이고, R4는 C1―6알킬을 나타내고, p는 0,1 또는 2이고, X는 ―CH2―, ―C〓O, O 또는 S이고, n은 4내지 10의 정수이고, m은 3내지 8의 정수이다.
  2. 제1항에 있어서, R1및 R2중 어느 하나 또는 모두가 분지쇄 C1―6알킬기인 화합물.
  3. 제1항 또는 2항에 있어서, p가 0인 화합물.
  4. 제1항 내지 3항 중 어느 한 항에 있어서, n이 5 내지 8의 정수인 화합물.
  5. 제1항 내지 4항 중 어느 한 항에 있어서, m이 4 내지 6의 정수인 화합물.
  6. 하기 일반식(I)의 화합물 및 이들의 염.
    1―〔6―옥소―6―(4―히드록시―3,5―디―t―부틸페닐)헥실〕피페리딘, 1―〔8―옥소―8―(4―히드록시―3,5―디―t―부틸페닐)옥틸〕피페리딘, 1―〔6―(4―히드록시―3,5―디―t―부틸페닐)헥실〕피페리딘, 1―〔8―(4―히드록시―3,5―디―t―부틸페닐)옥틸〕피페리딘, 1―〔7―(4―히드록시―3,5―디―t―부틸)티오페녹시―헵틸〕피페리딘, 1―〔7―(4―히드록시―3,5―디―t―부틸)페녹시헵틸〕피페리딘, 1―〔7―(4―옥소―7―(4―히드록시 3,5―디―t―부틸)헵틸〕피페리딘.
  7. (a)X가 O 또는 S인 화합물(I)을 제조 하기 위하여, 하기 일반식(II)의 화합물과 하기 일반식(III)의 화합물을 반응시키거나
    (상기 식 중, X1은 O 또는 S이고, m, n, p, R1, R2, R3및 R4는 일반식(I)에 정의된 바와 같고, L1은 친핵제와 치환가능한 기임), (b)하기 일반식(IV)의 화합물과 하기 일반식(V)의 화합물을 반응시키거나
    (상기 식 중, X, m, n, p, R1, R2, R3및 R4는 일반식(I)에 정의된 바와 같고, L2은 이탈기임), (c)하기 일반식(VI)의 화합물과 R1및 (또는) R2기를 도입시키는데 기여하는 화합물을 반응시키거나
    (상기 식 중, R1a및 R2a중 하나는 수소 원자이고, 다른 하나는 수소 원자, 할로겐, C1―6알킬 또는 페닐 중에서 선택되고, X, m, n, p, R1, R2, R3및 R4는 일반식(I)에 정의된 바와 같음), (d)X가 ―CH2―, S 또는 O인 화합물을 제조하기 위하여, 하기 일반식(VII) 또는 (VIII)의 아미드를 환원시키거나, 또는
    (e)일반식(I)의 화합물을 일반식(I)의 다른 화합물로 전환시키고, 계속하여 필요한 경우 염을 형성시키는 것을 포함하는, 상기 일반식(I)의 화합물을 제조 방법.
  8. 상기 일반식(I)의 화합물 또는 그의 제약상 허용되는 염의 유효량을 이를 필요로 하는 환자에게 투여하는 것을 포함하는, 자유 라디칼 관련 질환의 치료 방법.
  9. 상기 일반식(II)의 화합물 또는 그의 제약상 허용되는 염의 유효량을 이를 필요로 하는 환자에게 투여하는 것을 포함하는, 포유 동물의 뇌 세포에서 칼슘의 축적에 의해 발명되거나 또는 악화되는 상태 또는 질병의 치료방법.
  10. 유리 라디칼 관련 질환의 치료용 의약의 제조에 있어서의 상기 일반식(I)의 화합물 또는 그의 제약상 허용되는 염의 용도.
  11. 포유 동물의 뇌 세포에서 칼슘의 축적에 의해 발병되거나 또는 악화되는 상태 또는 질병의 치료용 의약의 제조에 있어서의 상기 일반식(I)의 화합물 또는 그의 제약상 허용되는 염의 용도.
  12. 상기 일반식(I)의 화합물 또는 그의 제약상 허용되는 염과 제약상 허용되는 담체 또는 부형제를 함유하는 제약 조성물.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019950702552A 1992-12-22 1993-12-16 칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists) KR950704284A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929226718A GB9226718D0 (en) 1992-12-22 1992-12-22 Compounds
GB939321808A GB9321808D0 (en) 1993-10-22 1993-10-22 Compounds
GB9226718.6 1993-10-22
GB9321808.9 1993-10-22
PCT/EP1993/003629 WO1994014786A1 (en) 1992-12-22 1993-12-16 Piperidine derivatives as calcium channel antagonists

Publications (1)

Publication Number Publication Date
KR950704284A true KR950704284A (ko) 1995-11-17

Family

ID=26302202

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702552A KR950704284A (ko) 1992-12-22 1993-12-16 칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists)

Country Status (8)

Country Link
EP (1) EP0675883A1 (ko)
JP (1) JPH08504792A (ko)
KR (1) KR950704284A (ko)
CN (1) CN1092415A (ko)
AU (1) AU5833494A (ko)
CA (1) CA2152394A1 (ko)
MX (1) MX9400070A (ko)
WO (1) WO1994014786A1 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
JP3588734B2 (ja) * 1996-07-26 2004-11-17 コニカミノルタホールディングス株式会社 電子写真感光体
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
WO1999043658A1 (en) 1998-02-27 1999-09-02 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US7186726B2 (en) 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6943168B2 (en) 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6951862B2 (en) 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
KR100740477B1 (ko) * 1999-12-21 2007-07-19 미쯔비시 웰 파마 가부시키가이샤 신경계 장애의 치료 및/또는 예방약
AU2006263564A1 (en) * 2005-06-29 2007-01-04 Merck Sharp & Dohme Corp. 4-fluoro-piperidine T-type calcium channel antagonists
CN113226468A (zh) 2018-06-27 2021-08-06 康奈尔大学 作为hcn1拮抗剂的经取代的烷基苯酚

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3233828A1 (de) * 1982-09-11 1984-03-15 Basf Ag, 6700 Ludwigshafen Aryloxyalkylamine, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DE3421810A1 (de) * 1984-06-12 1985-12-12 Basf Ag, 6700 Ludwigshafen Phenylalkylamine - bioregulatoren
DE3706585A1 (de) * 1987-02-25 1988-09-08 Schering Ag Aryl- und aryloxy-substituierte tert.-alkylenamine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
PT100639A (pt) * 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina

Also Published As

Publication number Publication date
EP0675883A1 (en) 1995-10-11
WO1994014786A1 (en) 1994-07-07
CA2152394A1 (en) 1994-07-07
CN1092415A (zh) 1994-09-21
JPH08504792A (ja) 1996-05-21
MX9400070A (es) 1994-07-29
AU5833494A (en) 1994-07-19

Similar Documents

Publication Publication Date Title
KR950704284A (ko) 칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists)
CA2036876A1 (fr) Derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR900006318A (ko) 피페리디닐 벤즈이미다졸
DE3276940D1 (en) Imidazole derivatives, process for their preparation and pharmaceutical products containing them
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
KR910002802A (ko) 1,2,3,4-테트라히드로-9-아크리딘아민의 유도체
KR950005823A (ko) 5-아미노-8-메틸-7-피롤리디닐퀴놀린-3-카르본산유도체
ATE178903T1 (de) Sulfamat-derivate von 1,3,5(10)-estratrien- derivaten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
NO995590L (no) 20-Aryl-5<alfa>-pregnan-derivater
KR890016009A (ko) 1,2,5,6-테트라히드로 피리딘유도체, 이들의 제조방법, 의약으로서 이들의 용도 및 이들을 함유하는 조성물
ATE108440T1 (de) Arylaralkylether, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
KR940003953A (ko) 1. 4-벤조디옥산 유도체
HUT50327A (en) Process for producing 2-square brackets open /piperidin-4-yl/-methyl square brackets closed-1,2,3,4-tetrahydro-isoquinoline derivatives and pharmaceutical compositions comprising same
KR940007020A (ko) 피레리딘 유도체, 이것의 제법 및 이것의 치료에의 이용
FR2655043B1 (fr) Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR910004563A (ko) 4,4-이중 치환된 피페리딘 유도체들과 그 화합물을 함유하는 약제학적 조성물 및 그것들의 제조 방법
KR970704685A (ko) 신경이완제로서 유용한 N-치환 아자비시클로헵탄 유도체(N-Substituted Azabicycloheptane Derivatives Useful as Neuroleptics)
DE69500274T2 (de) Thiazin- oder Thiomorpholinderivate
KR920002517A (ko) 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법
ATE10743T1 (de) Benzopyranylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel und zwischenprodukte.
ATE196080T1 (de) Verwendung von diphenylethanderivaten zur herstellung eines arzneimittels zur behandlung von glaukom
DE69300318T2 (de) Flavonderivate.
KR960017669A (ko) 양쪽성 3환식 화합물
HUT47266A (en) Process for production of benzimidasole-derivatives and medical compositions containing them

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid